Company / Financials
RenovoRx, Inc. Financials
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$43.0K
FY2025 · 0.0% YoY
Net Income
-$8.8M
FY2025 · +13.9% YoY
Profit Margin
-20497.7%
FY2025 · net income / revenue
ROE
-196.8%
FY2025 · return on equity
Total Assets
$8.1M
FY2025
Total Debt
-
FY2025
Equity
$4.5M
FY2025
ROA
-108.9%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.16 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$43.0K0.0% YoYNet Income HistoryProfit after all expenses and taxes-$8.8M+13.9% YoYGross Profit HistoryRevenue minus cost of goods sold$43.0K0.0% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$0Operating Income HistoryProfit from core business operations before interest and taxes-$11.0M+3.7% YoYSG&A Expense HistorySelling, general, and administrative expenses$5.0M-12.9% YoYR&D Expense HistoryResearch and development spending$6.0M+6.3% YoYIncome Tax HistoryTotal income tax expense$2.0KEPS (Basic) HistoryBasic earnings per share-$0.40+59.6% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.40+59.6% YoY